Urology
Volume 68, Supplement , Page 2, November 2006

PD-01.04:

Phase II dose finding study of ozarelix, an LHRH antagonist, in patients with inoperable prostate cancer

  • F.M.J. Debruyne

      Affiliations

    • Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
    • ,
  • K. Neykov

      Affiliations

    • Oncology Dispensary Varna, Varna, Bulgaria
    • ,
  • V.D. Taskova

      Affiliations

    • Inter District Dispensary of Oncology, Varna, Bulgaria
    • ,
  • S. Stratev

      Affiliations

    • University Hospital, Pleven, Bulgaria
    • ,
  • A. Bantchev

      Affiliations

    • Oncology Dispensary Schumen, Schumen, Bulgaria
    • ,
  • S.S. Karanikolov

      Affiliations

    • National Oncological Hospital, Sofia, Bulgaria
    • ,
  • S. Chawla

      Affiliations

    • Spectrum Pharmaceuticals, Inc., Irvine, CA, USA
    • ,
  • G. Lenaz

      Affiliations

    • Spectrum Pharmaceuticals, Inc., Irvine, CA, USA
    • ,
  • M. Peukert

      Affiliations

    • Zentaris GmbH, Frankfurt, Germany
    • ,
  • J. Engel

      Affiliations

    • Zentaris GmbH, Frankfurt, Germany

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0090-4295(06)00993-9

doi:10.1016/j.urology.2006.08.005

Urology
Volume 68, Supplement , Page 2, November 2006

Article Tools